Country for PR: United States
Contributor: PR Newswire New York
Monday, February 15 2021 - 11:08
TCAI Leader Participates in Clinical Trial for Catheter that May Prevent Rare Life-Threatening Complication During Cardiac Ablation
AUSTIN, Texas, Feb. 15, 2021 /PRNewswire-AsiaNet/--

A physician with the Texas Cardiac Arrhythmia Institute (TCAI) at St. David's 
Medical Center ( ) is among the first in the world to 
participate in a clinical trial to evaluate the safety and efficacy of a new 
cardiac-specific catheter used during pulsed field ablation (PFA), a new 
approach to treating patients with atrial fibrillation (A Fib). Andrea Natale, 
M.D., F.H.R.S., F.A.C.C., F.E.S.C., cardiac electrophysiologist and executive 
medical director of TCAI, recently participated in the first-in-human trials of 
this catheter in Europe.

PFA uses a controlled electric field instead of thermal energy to ablate or 
burn cardiac tissue during simple and complex ablation procedures through a 
process known as irreversible electroporation (IRE). This technique may prevent 
collateral damage to surrounding tissue during ablation.

"The process of irreversible electroporation is an exciting new approach in our 
field, as it may reduce the risk of complications such as pulmonary stenosis 
(narrowing of an artery) or esophageal fistulas (abnormal connections between 
the esophagus and heart). While rare, esophageal fistulas can be life 
threatening," Dr. Natale said. "This treatment may also reduce or eliminate 
chest pain that often occurs following surgery, as well as result in a shorter 

Physicians will test the catheter on approximately 40 patients in Europe, with 
in-human trials expected in the U.S. this summer. 

Media Contact:
Stacy Slayden
Elizabeth Christian Public Relations 
+1-254-592-2767 cell

SOURCE: Texas Cardiac Arrhythmia Institute at St. David’s Medical Center